These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

735 related articles for article (PubMed ID: 19038731)

  • 1. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
    Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR pathway in advanced non-small cell lung cancer.
    Merlo V; Longo M; Novello S; Scagliotti GV
    Front Biosci (Schol Ed); 2011 Jan; 3(2):501-17. PubMed ID: 21196393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
    Pirker R; Minar W; Filipits M
    Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights in drug development for the non-small cell lung cancer therapy.
    Gridelli C; Rossi A; Maione P; Ferrara C; Del Gaizo F; Guerriero C; Nicolella D; Palazzolo G; Falanga M; Colantuoni G
    Front Biosci; 2008 May; 13():5108-19. PubMed ID: 18508573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
    J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
    Chung CH; Seeley EH; Roder H; Grigorieva J; Tsypin M; Roder J; Burtness BA; Argiris A; Forastiere AA; Gilbert J; Murphy B; Caprioli RM; Carbone DP; Cohen EE
    Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):358-65. PubMed ID: 20086114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor inhibition in solid tumours.
    Ganti AK; Potti A
    Expert Opin Biol Ther; 2005 Sep; 5(9):1165-74. PubMed ID: 16120047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.
    Dziadziuszko R; Jassem J
    Ann Oncol; 2012 Sep; 23 Suppl 10():x193-6. PubMed ID: 22987961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of tyrosine kinase inhibitors in lung cancer.
    Ansari J; Palmer DH; Rea DW; Hussain SA
    Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical treatment of non-small-cell lung cancer.
    Buter J; Giaccone G
    Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463
    [No Abstract]   [Full Text] [Related]  

  • 14. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
    Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
    Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
    Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
    J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer.
    Joy AA; Butts CA
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S24-9. PubMed ID: 19362943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
    Cavazzoni A; Alfieri RR; Cretella D; Saccani F; Ampollini L; Galetti M; Quaini F; Graiani G; Madeddu D; Mozzoni P; Galvani E; La Monica S; Bonelli M; Fumarola C; Mutti A; Carbognani P; Tiseo M; Barocelli E; Petronini PG; Ardizzoni A
    Mol Cancer; 2012 Dec; 11():91. PubMed ID: 23234355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Neal JW; Heist RS; Fidias P; Temel JS; Huberman M; Marcoux JP; Muzikansky A; Lynch TJ; Sequist LV
    J Thorac Oncol; 2010 Nov; 5(11):1855-8. PubMed ID: 20975380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.